Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Pouruchis Bhiwandiwalla

Gynecology Raleigh, NC Medical Doctor

NPI 1376576967 CMS profile 153490

3100 Duraleigh Rd, Suite 307, Raleigh, NC 27612

Open in the dashboard

General payments

$157,688

186 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$5

5 holdings reported · through program year 2024

Research they led as principal investigator

$2,105,246 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Pouruchis Bhiwandiwalla of Raleigh, NC is reported in the CMS Open Payments database as having received $157,688 across 186 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,105,246 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $5 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $17 1
2023 General $5,558 12
2022 General $27,298 34
2021 General $22,811 22
2020 General $15,120 16
2019 General $86,884 101
2024 Ownership $1 1
2023 Ownership $1 1
2022 Ownership $1 1
2021 Ownership $1 1
2020 Ownership $1 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pouruchis Bhiwandiwalla
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Pouruchis Bhiwandiwalla were reported at $0. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Pouruchis Bhiwandiwalla Gynecology median Middle half National median
2019 $86,884 $199 $66–$472 $163
2020 $15,120 $114 $42–$287 $114
2021 $22,811 $141 $42–$430 $132
2022 $27,298 $173 $52–$532 $149
2023 $5,558 $170 $57–$501 $160
2024 $17 $157 $50–$424 $164
2025 $0 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $151,252 161 payments
  2. Astellas Pharma US Inc $5,381 4 payments
  3. Exeltis, USA Inc. $631 3 payments
  4. Mayne Pharma Inc. $256 9 payments
  5. SCYNEXIS, Inc. $32 1 payment
  6. Myovant Sciences Inc. $30 2 payments
  7. Lupin Inc. $26 1 payment
  8. Sumitomo Pharma America, Inc. $18 1 payment
  9. Organon LLC $17 1 payment
  10. Duchesnay USA Incorporated $16 1 payment
  11. Other $28 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $123,475 49 payments
  2. Travel and Lodging $28,749 47 payments
  3. Food and Beverage $4,853 86 payments
  4. Consulting Fee $500 1 payment
  5. Education $111 3 payments
Products named General payments · program years 2019–2024
  1. Orilissa Endocrinology $86,221 96 payments
  2. ORIAHNN $43,201 44 payments
  3. ORILISSA Womens Health $40,502 41 payments
  4. Veozah $5,301 3 payments
  5. SLYND $615 2 payments
  6. SELECT-OB PLUS DHA $615 2 payments
  7. NEXTSTELLIS $124 1 payment
  8. SKYRIZI $101 1 payment
  9. LO LOESTRIN FE $91 6 payments
  10. MYFEMBREE $48 3 payments
  11. Other $133 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

48

Median for Obstetrics & Gynecology: 65

Drug cost

$10,041

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

66.7%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 17 $8,131
Estradiol Generic 16 $1,264
Valacyclovir Valacyclovir Hcl Brand 15 $646

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record